Dataset Information


Regulation of aldosterone secretion by Cav1.3.

ABSTRACT: Aldosterone-producing adenomas (APAs) vary in phenotype and genotype. Zona glomerulosa (ZG)-like APAs frequently have mutations of an L-type calcium channel (LTCC) CaV1.3. Using a novel antagonist of CaV1.3, compound 8, we investigated the role of CaV1.3 on steroidogenesis in the human adrenocortical cell line, H295R, and in primary human adrenal cells. This investigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold selectivity for the vascular LTCC, CaV1.2, over CaV1.3. In H295R cells transfected with wild-type or mutant CaV1.3 channels, the latter produced more aldosterone than wild-type, which was ameliorated by 100??M of compound 8. In primary adrenal and non-transfected H295R cells, compound 8 decreased aldosterone production similar to high concentration of nifedipine (100??M). Selective CaV1.3 blockade may offer a novel way of treating primary hyperaldosteronism, which avoids the vascular side effects of CaV1.2-blockade, and provides targeted treatment for ZG-like APAs with mutations of CaV1.3.


PROVIDER: S-EPMC4876952 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5424579 | BioStudies
2015-01-01 | S-EPMC4454794 | BioStudies
2015-01-01 | S-EPMC4387203 | BioStudies
2018-01-01 | S-EPMC6958178 | BioStudies
2015-01-01 | S-EPMC4547250 | BioStudies
2013-01-01 | S-EPMC4595045 | BioStudies
2017-01-01 | S-EPMC6596555 | BioStudies
2014-01-01 | S-EPMC4124865 | BioStudies
2017-01-01 | S-EPMC5554211 | BioStudies
1000-01-01 | S-EPMC5506795 | BioStudies